// App-Quantinova.ai

4412 : c-Myc-driven lymphomas require calcium-modulating cyclophilin ligand (CAML) for survival and proliferation

Researchers

Presenter

  • Jennifer C. Shing

Principal Investigators

  • Lonn D. Lindquist

  • Richard J. Bram

Medical Centers

  • Mayo Clinic, Rochester, MN

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • B cell lymphomas

  • Lymphomas

  • Solid malignancies

Biomarkers

  • B-cell lymphoma 2

  • c-Jun N-terminal kinase

Drug/Treatment

  • Tamoxifen

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved